Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002430 · ClinicalTrials.gov registry record · NA
A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations
A NA study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- NA
- Development phase
- 220
- Enrollment target
NCT00002430: Completed NA study, sponsored by Merck Sharp & Dohme.
NCT00002430 is a NA study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 220 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002430, a NA study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two different anti-HIV drug combinations, one that contains nelfinavir (NFV) and one that does not. The best dosing schedule for indinavir (IDV) also will be studied.
Interventions
- DRUG Lamivudine
- DRUG Indinavir sulfate
- DRUG Stavudine
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Phase | NA |
What the finished NCT00002430 record still lists
NCT00002430 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 4 interventions - of which Lamivudine is the first listed.
NCT00002430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002430 about?
NCT00002430 is a clinical study titled "A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations". The purpose of this study is to compare two different anti-HIV drug combinations, one that contains nelfinavir (NFV) and one that does not. The best dosing schedule for indinavir (IDV) also will be studied.
What is the current status of trial NCT00002430?
This trial is currently completed. It is a NA study. The enrollment target is 220 participants.
What interventions are being tested in trial NCT00002430?
The interventions under investigation include: Lamivudine (DRUG), Indinavir sulfate (DRUG), Stavudine (DRUG), Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002430?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002430's enrollment target sits among peer trials
220 481st of 2000 higher than 1,516 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer